Sunday, December 9, 2007

[StemCells] Lack of $$$ for organ growth

Lab-grown human organs: Companies lack funding to meet expectations
COMPANIES STRUGGLE FOR FUNDING, AND FEW PRODUCTS REACH MARKET
By Steve Johnson
Mercury News
Article Launched: 12/09/2007 01:50:38 AM PST

By manipulating cells in a laboratory, Stanford University
researchers have created livers that closely resemble those of rats
and pigs.

Executives at Cerco Medical of San Francisco have fabricated human
islet cells into a patch the size of a business card that they
believe one day could be attached to a diabetic's pancreas to make
insulin.

And a Wake Forest University School of Medicine researcher has grown
human bladders.

Yet after more than two decades of effort by biotechnology firms and
non-profit institutions, the dream of replacing people's defective
organs and other body parts with lab-grown versions has largely
remained unfulfilled.

Although investors have pumped more than $4.5 billion into so-called
tissue engineering companies since 1990, according to federal
estimates, only a smattering of lab-made skin and cartilage products
have been approved for sale.

Moreover, while the number of such companies has steadily grown, many
tissue engineering entrepreneurs have struggled to make a profit and
some say it's gotten harder to attract private money for their
businesses.

"I can't get the venture capitalists I've worked with for years to
return calls," said Scott King, chief executive at Cerco Medical, one
of the few companies in the Bay Area to dabble in the field. "There
is just no interest," he added, noting that the lack of financing has
forced him to temporarily halt studies of his insulin-producing patch.

----------------------------------------------------------
----------

Advertisement

----------------------------------------------------------
----------
Meanwhile, companies such as Cerco are facing increasing competition
from foreign tissue engineering businesses, which tend to get a
greater share of their money from government sources. As a
result, "other countries may increasingly challenge U.S. leadership
in this field," warned a report issued in June by several U.S.
agencies.
About 20 years ago, when tissue engineering first took off in this
country, the interest was primarily fueled by the dearth of hearts,
kidneys, lungs, livers and other donor organs for transplants. That
shortage has not eased.

Although nearly 30,000 people in the United States received such
transplants last year, the waiting list for organs tops 100,000,
according to the Organ Procurement and Transplantation Network, which
Congress created in 1984.

Mechanical organs, metal hip joints and other synthetic body parts
have helped fill the need. But such devices sometimes don't last as
long as living tissue, and can cause blood clots and infection. So if
firms could bioengineer replacements, many experts say, the potential
profits could be huge.

A federal study three years ago estimated that the global market for
bioengineered tissues and other so-called regenerative-medicine
products could exceed $500 billion within two decades. Yet current
annual sales of such products total only about $1.5 billion,
according to Michael Lysaght, who tracks that data as Director of the
Center for Biomedical Engineering at Brown University in Rhode Island.

That hasn't deterred a growing number of entrepreneurs from entering
the field. Since 2000, the industry worldwide has grown from 70
companies with 3,100 full-time employees to about 160 firms with
6,100 employees today, Lysaght said. The annual investments by public
and private sources also has risen over that same period, from about
$610 million to $900 million.

Still, experts say profits have remained elusive for most tissue-
engineering companies in this country, including Advanced Tissue
Sciences of La Jolla. It managed to get a product for treating burns
approved for sale by the U.S. Food and Drug Administration in 1997
and another approved in 2001 for treating ulcers and other wounds.
Yet the products generated little revenue and the company filed for
bankruptcy in October 2001.

"What's happened has been terrible," said Gail Naughton, who co-
founded the company in 1987 and now is dean of San Diego State
University's College of Business Administration.

She attributes Advanced Tissue Sciences' failure to a variety of
factors, but said it partly reflected a tendency many early tissue-
engineering businesses had of overestimating how much hospitals and
insurers would pay for their products.

"We were all making it up as we went along," she said. "Anytime you
are the first ever, there are going to be challenges."

Others in the industry didn't realize how difficult developing body
parts would be, added Rosemarie Hunziker of the National Institute of
Biomedical Imaging and Bioengineering.

"This is an incredibly complex field," she said.

Nonetheless, many companies and research institutions are still
pursuing the hope that organs and other body parts one day can be
grown like so much farm produce to rejuvenate patients suffering from
a wide range of ailments. And they are making progress, although it
could be years before most of them get a product on the market.

"The science is advancing," said William Wagner, of the McGowan
Institute for Regenerative Medicine in Pennsylvania. "The level of
sophistication you see in the scientific literature has markedly
increased in the last five years."

Considerable optimism centers on the promise of stem cells, which can
be coaxed to become different types of tissue and which are
relatively easy to grow in large quantities. Two Bay Area companies
hoping to use stem cells to generate healthy tissue are StemCells of
Palo Alto and Geron of Menlo Park.

But other cells that have matured beyond the stem-cell phase also
have proved useful for tissue engineering, as Anthony Atala of Wake
Forest has shown.

Atala has drawn worldwide acclaim for being the first scientist to
implant laboratory-grown organs in people. He accomplished that feat
in 1999 using bladders he created while at Harvard Medical School.

To lessen the likelihood of the organs being rejected by the
patients' bodies, he made them from the patients' own tissue, using
urothelial cells from the inside lining of their original bladders
and their muscle cells.

The cells then were grown in a laboratory until they reached
sufficient number to be placed onto biodegradable scaffolds shaped
like bladders. After about eight weeks, the so-called neo-bladders
were implanted into seven children and adults, and the scaffolds
eventually dissolved.

Atala - who says the patients' urinary incontinence has been improved
by the implants - is now helping a Pennsylvania company, Tengion,
conduct more studies of the bladders in people with the idea of
eventually seeking federal approval to sell the organs commercially.

The variety of potential applications for lab-grown tissues is
seemingly limitless.

Some Japanese researchers reported in March that they have developed
a promising technique for growing whole teeth, which otherwise are
incapable of regenerating themselves.

The military is studying ways to grow tissue to replace burned skin,
repair damaged limbs and even detect biological or chemical warfare
agents.

Still other efforts are under way to develop bioengineering heart
valves, breasts, vaginae, nerves, blood vessels and bone.

But the greatest goal remains to make whole replacement organs for
people, said Dr. Geoffrey Gurtner, the Stanford researcher who has
grown the rat and pig livers.

"That is in the long term, where tissue engineering will really be
important," he said. "It will be a game-changing paradigm in
medicine."

----------------------------------------------------------
Contact Steve Johnson at sjohnson@mercurynews.com or (408) 920-5043.

http://www.contracostatimes.com/technology/ci_7675722?nclick_check=1

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Yahoo! News

Fashion News

What's the word on

fashion and style?

Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

Best of Y! Groups

Check out the best

of what Yahoo!

Groups has to offer.

.

__,_._,___

No comments:



about stem cell research
adult stem cell
adult stem cell research
adult stem cells
against stem cell
against stem cell research
anti stem cell
anti stem cell research
autologous stem cell
autologous stem cell transplant
benefits of stem cell research
blood stem cells
bone marrow stem cells
bush stem cell
california stem cell
cancer stem cell
cancer stem cells
cell stem cell
cons of stem cell research
cord blood stem cell
cord blood stem cells
cord stem cells
diabetes stem cell
embryonic stem cell
embryonic stem cell research
embryonic stem cells
for stem cell research
funding for stem cell research
harvard stem cell
harvard stem cell institute
hematopoietic stem cell
hematopoietic stem cells
history of stem cell research
human embryonic stem cell
human embryonic stem cell research
human embryonic stem cells
international stem cell
mesenchymal stem cell
mesenchymal stem cells
neural stem cell
neural stem cells
nih stem cell
pluripotent stem cells
pro stem cell
pro stem cell research
pros and cons of stem cell
pros and cons of stem cell research
stem cell
stem cell bank
stem cell bill
stem cell biology
stem cell companies
stem cell conference
stem cell controversy
stem cell cures
stem cell debate
stem cell differentiation
stem cell ethics
stem cell funding
stem cell heart
stem cell information
stem cell institute
stem cell line
stem cell lines
stem cell news
stem cell policy
stem cell reasearch
stem cell reaserch
stem cell reseach
stem cell research
stem cell research articles
stem cell research bill
stem cell research controversy
stem cell research debate
stem cell research enhancement act
stem cell research ethics
stem cell research facts
stem cell research funding
stem cell research pros
stem cell research pros and cons
stem cell reserach
stem cell reserch
stem cell technologies
stem cell technology
stem cell therapy
stem cell transplant
stem cell transplantation
stem cell transplants
stem cell treatment
stem cell treatments
stem cell veto
stem cells
stem cells research
support stem cell research
types of stem cells
umbilical cord stem cells
what are stem cells
what is a stem cell
what is stem cell
what is stem cell research